Axsome Therapeutics, Inc. Forecast, price target & analysts
Axsome Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Axsome Therapeutics, Inc. Classifications & Recommendation:
Axsome Therapeutics, Inc. Price Target
| Target Price | $185.13 |
| Price | $109.39 |
| Potential |
69.24%
register free of charge
|
| Number of Estimates | 20 |
|
20 Analysts have issued a price target Axsome Therapeutics, Inc. 2026 .
The average Axsome Therapeutics, Inc. target price is $185.13.
This is
69.24%
register free of charge
$220.50
101.57%
register free of charge
$149.48
36.65%
register free of charge
|
|
| A rating was issued by 25 analysts: 24 Analysts recommend Axsome Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Axsome Therapeutics, Inc. stock has an average upside potential 2026 of
69.24%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 385.69 | 623.36 |
| 42.53% | 61.62% | |
| EBITDA Margin | -71.09% | -26.22% |
| 14.68% | 63.11% | |
| Net Margin | -74.47% | -29.11% |
| 15.77% | 60.91% |
21 Analysts have issued a sales forecast Axsome Therapeutics, Inc. 2025 . The average Axsome Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Axsome Therapeutics, Inc. EBITDA forecast 2025. The average Axsome Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
21 Axsome Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Axsome Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.99 | -3.64 |
| 13.66% | 39.23% | |
| P/E | negative | |
| EV/Sales | 8.25 |
21 Analysts have issued a Axsome Therapeutics, Inc. forecast for earnings per share. The average Axsome Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Axsome Therapeutics, Inc....
Current Axsome Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B of A Securities |
Locked
➜
Locked
|
Locked | Aug 05 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 05 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Aug 04 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jun 12 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 10 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Jun 09 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Jun 03 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
B of A Securities:
Locked
➜
Locked
|
Aug 05 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 05 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Aug 04 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jun 12 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 10 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Jun 09 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Jun 03 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
